Efficacy and safety of elbasvir/grazoprevir treatment for HCV patients in real-life clinical practice: Results from Spanish Hepa-C cohort
Latest Information Update: 15 Jul 2020
Price :
$35 *
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 14 Nov 2017 New trial record
- 24 Oct 2017 Results (n=178) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases